Bypass grafting, coronary artery

Prior to myocardial infarction, coronary artery bypass graft (CABG), peripheral artery disease, cerebrovascular accident, or aspirin use... 

Do not use combination therapy in patients at high-risk for bleeding or if the need for urgent coronary artery bypass graft (CABG) cannot be excluded... 

Previous protamine exposure (e.g., during coronary artery bypass graft, or NPH insulin products containing protamine zinc)... 

CABG coronary artery bypass graft (surgery)... 

Coronary artery bypass graft surgery Pulmonary resection Thoracoabdominal esophagectomy Drugs 13... 

CABG Coronary artery bypass grafting DBP Diastolic blood pressure... 

Coronary artery bypass graft surgery Thoracic surgery whereby parts of a saphenous vein from a leg or internal mammary artery from the arm are placed as conduits to restore blood flow between the aorta and one or more coronary arteries to bypass the coronary artery stenosis (occlusion). 

Scheier, M. F., K A. Matthews, J. F. Owens, R. Schulz, M. W. Bridges, G. J. Magovem and C. S. Carver, Optimism and Rehospitalization after Coronary Artery Bypass Graft Surgery , Archives of Internal Medicine 159, no. 829-35 (1999)... 

In patients with NSTE ACS, clinical practice guidelines recommend either PCI or coronary artery bypass grafting revascularization as an early treatment for high-risk patients, and that such an approach also be considered for moderate-risk patients. An early invasive approach results in fewer Mis, less need for revascularization procedures over the next year after hospitalization, and lower cost than the conservative medical stabilization approach. 

In patients undergoing coronary artery bypass grafting, clopidogrel (but not aspirin) should be withheld at least 5 days and preferably 7 days before the procedure. 

Apart from its role in atherogenesis, recent observations suggest that high Lp(a) levels are also associated with early occlusion of coronary artery bypass grafts and femoropopliteal vein grafts (H33, W17). In this situation, however, a thrombotic rather than an atherogenic mechanism may be responsible for the events. 

Modifications of the Bratton-Marshall method mentioned in Section IV.D.3.g can be used for sensitive spectrophotometric detection and determination of primary aromatic and heterocyclic amines. Thus, a simple spectrophotometric determination of the cardioprotective agent acadesine (142) was developed, to measure concentrations of the drug in plasma during intravenous infusion to patients undergoing coronary artery bypass graft surgery336. 

Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival overview of 10 year results from randomised trials by the Coronary Artery Bypass Graft Trialists Collaboration. The Lancet 1994 344 563-70. 

Acute coronary syndrome For patients with acute coronary syndrome (unstable angina/non-Q-wave Ml) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or coronary artery bypass graft (CABG), clopidogrel has been shown to decrease the rate of a combined endpoint of cardiovascular death. Ml, or stroke, as well as the rate of a combined endpoint of cardiovascular death. Ml, stroke, or refractory ischemia. 

Meloxicam is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery)... 

Dilsizian V, Bonow RO, Cannon RO, III, Tracy CM, Vitale DF, McIntosh CL et al. The effect of coronary artery bypass grafting on left ventricular systolic function at rest evidence for preoperative subclinical myocardial ischemia. Am J Cardiol 1988 61 1248-1254... 

Iskandrian AS, Hakki AH, Kane SA, Goel IP, Mundth ED, Hakki AH et al. Rest and redistribution thallium-201 myocardial scintigraphy to predict improvement in left ventricular function after coronary arterial bypass grafting. Am I Cardiol 1983 51 1312-1316... 

Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989 64 860-865... 

CABG PATCH = Coronary Artery Bypass Graft (CABG) Patch Trial. 

Survival curves in MADIT II did not separate until 9 months after enrollment, raising the question of when an ICD should be implanted after MI or revascularization. Two notable negative primary prevention trials may answer this question. The Coronary Artery Bypass Graft Patch (CABG-Patch) Trial evaluated whether primary prevention with ICD at the time of surgical revascularization in patients with EF < 35% and a positive SAECG would reduce total mortality [33]. At 32 months follow-up, no difference was found, suggesting that there is no additional benefit to ICD therapy at the time of revascularization. 

---